Poland Pharmaceuticals and Healthcare Report Q4 2010

  • ID: 1298500
  • August 2010
  • Region: Poland
  • 85 Pages
  • Business Monitor International
1 of 4


  • Bioton
  • Eli Lilly
  • Gedeon Richter
  • GlaxoSmithKline
  • Krka
  • Lek
  • MORE

Business Monitor International's Poland Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Poland's pharmaceuticals and healthcare industry.

Propped up by its large population, Poland has surfaced as one of the most important global emerging markets, with its value in 2009 calculated at PLN30.25bn (US$10.26bn) at retail prices. Over a five-year period, BMI forecasts that pharmaceutical sales in Poland will increase at a compound annual growth rate (CAGR) of 6.7% in zloty terms, or 9.1% in US dollar terms. By absolute value, the market will have grown to PLN41.80bn (US$15.83bn) by 2014, making Poland the ninth-fastest growing market globally.

In BMI’s Pharmaceuticals & Healthcare Business Environment Ratings (BERs) for Emerging Europe in Q410, Poland remains in second place, supported by increased optimism surrounding the country’s market outlook. On a global basis, Poland is 17th of the total of 83 markets surveyed in our pharmaceutical universe. However, the country’s READ MORE >

Note: Product cover images may vary from those shown
2 of 4


  • Bioton
  • Eli Lilly
  • Gedeon Richter
  • GlaxoSmithKline
  • Krka
  • Lek
  • MORE

Executive Summary

SWOT Analysis
- Poland Pharmaceuticals Industry SWOT
- Poland Political SWOT
- Poland Economic SWOT
- Poland Business Environment SWOT

Pharmaceutical Business Environment Ratings
- Table: Emerging Europe – Regional Pharmaceutical Business Environment Ratings, Q410
- Rewards
- Risks
- Poland - Market Summary

Regulatory Regime
- Intellectual Property Developments
- Pricing And Reimbursement Regime
- Pricing Policies
- Reimbursement Policies
- Recent Developments in Reimbursement System
- Marketing Regulations
- Other Regulatory Developments

Industry Trends and Developments
- Epidemiology
- Table: Disease Burden In CEE
- Healthcare System
- Healthcare Funding
- Healthcare Reforms
- Health Insurance
- Research And Development
- Medical Devices

Industry Forecast Scenario
- Overall Market Forecast
- Key Growth Factors – Industry
- Key Growth Factors – Macroeconomic
- Table: Poland - Economic Activity
- Prescription Drug Market Forecast
- Patented Product Market Forecast
- Generic Drug Market Forecast
- OTC Medicine Market Forecast
- Medical Device Market Forecast
- Pharmaceutical Trade Forecast
- Other Healthcare Data Forecasts
- Key Risks To BMI’s Forecast Scenario

Competitive Landscape
- Pharmaceutical Industry
- Domestic Industry
- Domestic Company Developments
- Foreign Industry
- Foreign Company Developments
- Biotechnology Sector
- Pharmaceutical Wholesale Sector
- Pharmaceutical Retail Sector
- Table: Poland’s Pharmacies & Pharmacy Market Ratios, 2004-2009

Company Profiles
- Leading Indigenous Companies
- Polpharma
- Bioton
- Leading Foreign Companies
- GlaxoSmithKline
- Eli Lilly
- Gedeon Richter
- Krka
- Lek (Novartis/Sandoz)

Country Snapshot: Poland Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)
- Table: Average Annual Wages, 2000-2012

BMI Methodology
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceuticals Business Environment Ratings
- Risk/Reward Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
- Forecast Tables

Note: Product cover images may vary from those shown
3 of 4

- Polpharma
- Bioton
- GlaxoSmithKline
- Eli Lilly
- Gedeon Richter
- Krka
- Lek

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • Pfizer, Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S